Forsberg M, Konopleva M
Haematologica. 2024; 109(12):3832-3834.
PMID: 39618293
PMC: 11609778.
DOI: 10.3324/haematol.2024.286233.
Bercier P, de The H
Cancers (Basel). 2024; 16(7).
PMID: 38611029
PMC: 11011038.
DOI: 10.3390/cancers16071351.
Ghiaur A, Doran C, Gaman M, Ionescu B, Tatic A, Cirstea M
Cancers (Basel). 2024; 16(6).
PMID: 38539495
PMC: 10969096.
DOI: 10.3390/cancers16061160.
Langdon K, Cosentino S, Wawryk O
Cancer Rep (Hoboken). 2024; 7(3):e2035.
PMID: 38507294
PMC: 10953833.
DOI: 10.1002/cnr2.2035.
Maeda T, Najima Y, Kamiyama Y, Nakao S, Ozaki Y, Nishio H
Int J Clin Oncol. 2024; 29(5):535-544.
PMID: 38494578
PMC: 11043120.
DOI: 10.1007/s10147-023-02465-0.
Evolution in treatment of acute promyelocytic leukemia: a major victory.
Tallman M
Haematologica. 2024; 109(2):367-368.
PMID: 38299725
PMC: 10828631.
DOI: 10.3324/haematol.2023.284421.
Differentiation Syndrome in Acute Leukemia: APL and Beyond.
Woods A, Norsworthy K
Cancers (Basel). 2023; 15(19).
PMID: 37835461
PMC: 10571864.
DOI: 10.3390/cancers15194767.
Pharmaceutical/Clinical Strategies in the Treatment of Acute Promyelocytic Leukemia: All-Trans Retinoic Acid Encapsulation by Spray-Drying Technology as an Innovative Approach-Comprehensive Overview.
Goncalves A, Rocha F, Estevinho B
Pharmaceuticals (Basel). 2023; 16(2).
PMID: 37259328
PMC: 9963698.
DOI: 10.3390/ph16020180.
Epidemiology and early mortality patterns of acute promyelocytic leukemia in the United States.
Sharma A, Yang J, Singh V
Ann Hematol. 2023; 102(5):1053-1062.
PMID: 36918414
DOI: 10.1007/s00277-023-05154-0.
An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial).
Wang H, Gong S, Li G, Yao Y, Zheng Y, Lu X
Blood Cancer J. 2022; 12(11):158.
PMID: 36404343
PMC: 9676182.
DOI: 10.1038/s41408-022-00753-y.
Safety and efficacy of Compound Huangdai Tablets combined with all-trans retinoic acid for treatment of acute promyelocytic leukemia: Clinical evidence and potential mechanisms.
Huang Q, Wang T, Xiong Y, Qu L, Yin Q, Zou W
Chin Herb Med. 2022; 14(1):154-165.
PMID: 36120125
PMC: 9476755.
DOI: 10.1016/j.chmed.2021.09.004.
Realgar (AsS), a traditional Chinese medicine, induces acute promyelocytic leukemia cell death via the Bcl-2/Bax/Cyt-C/AIF signaling pathway .
Li Z, Zhang R, Yin X, Li N, Cui S, Wang T
Aging (Albany NY). 2022; 14(17):7109-7125.
PMID: 36098742
PMC: 9512515.
DOI: 10.18632/aging.204281.
p53 as a unique target of action of cisplatin in acute leukaemia cells.
Kumar S, Tchounwou P
J Cell Mol Med. 2022; 26(17):4727-4739.
PMID: 35946055
PMC: 9443951.
DOI: 10.1111/jcmm.17502.
Atypical Rearrangements in APL-Like Acute Myeloid Leukemias: Molecular Characterization and Prognosis.
Guarnera L, Ottone T, Fabiani E, Divona M, Savi A, Travaglini S
Front Oncol. 2022; 12:871590.
PMID: 35494081
PMC: 9039303.
DOI: 10.3389/fonc.2022.871590.
Early death in acute promyelocytic leukemia: time to redefine risk groups.
Yisraeli Salman M, Ofran Y
Haematologica. 2022; 107(7):1498-1499.
PMID: 35081691
PMC: 9244806.
DOI: 10.3324/haematol.2021.280446.
The "7+3" regimen in acute myeloid leukemia.
Rowe J
Haematologica. 2022; 107(1):3.
PMID: 34985228
PMC: 8719100.
DOI: 10.3324/haematol.2021.280161.
History of Acute Promyelocytic Leukemia.
Sanz M, Barragan E
Clin Hematol Int. 2021; 3(4):142-152.
PMID: 34938986
PMC: 8690702.
DOI: 10.2991/chi.k.210703.001.
The cure of leukemia through the optimist's prism.
Kantarjian H, Jain N, Garcia-Manero G, Welch M, Ravandi F, Wierda W
Cancer. 2021; 128(2):240-259.
PMID: 34614211
PMC: 8738114.
DOI: 10.1002/cncr.33933.
Acute promyelocytic leukemia current treatment algorithms.
Yilmaz M, Kantarjian H, Ravandi F
Blood Cancer J. 2021; 11(6):123.
PMID: 34193815
PMC: 8245494.
DOI: 10.1038/s41408-021-00514-3.
Acute Promyelocytic Leukemia: A Long-Term Retrospective Study in Mexico.
Zapata-Canto N, Aguilar M, Arana L, Montano E, Ramos-Penafiel C, De la Pena J
J Hematol. 2021; 10(2):53-63.
PMID: 34007366
PMC: 8110230.
DOI: 10.14740/jh773.
